Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-TRD oral esketamine versus electroconvulsive therapy in treatment-resistant depression
2024-517485-42-00Phase 3Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of esketamine in major depressive disorder (MDD) and treatment-resistant depression (TRD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoints: Short-term treatment response at 8 weeks and Relapse during 12 months of maintenance treatment. Planned start Jul 2022; status: authorised.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on 2024-517485-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517485-42-00.